Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nitric Oxide During Cardiopulmonary Bypass in Neonates to Reduce AKI Risk
NCT04216927Phase 3Recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Jan 2023
- Primary completion
- Jun 2027
- Modality
- DNA Intercalators/Alkylators, Inhalation Devices
- Countries
- 1
01
Overview
Phase 3, randomised trial of nitric oxide in acute kidney injury (AKI) (2 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Acute Kidney Injury at 72 hours. Started Jan 2023; status: recruiting.
02
Drugs
nitric oxide
03
Conditions
acute kidney injury (AKI)
Beyond the preview
Go deeper on NCT04216927.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04216927.